A Phase I Trial of Tecogalan Sodium (DS-4152) Administered as an Infusion Every 21 Days
NCT00002136 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL
Last updated 2005-06-24
Summary
To evaluate the safety of different doses and dosing regimens of tecogalan sodium (DS-4152) and to establish the MTD at each of the different dosing schedules.
Conditions
- Sarcoma, Kaposi
- HIV Infections
Interventions
- DRUG
-
Tecogalan sodium
Sponsors & Collaborators
-
Daiichi Pharmaceuticals
lead INDUSTRY
Study Design
- Purpose
- TREATMENT
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
Countries
- United States
Study Locations
More Related Trials
-
Chemotherapy in Treating Patients With Advanced Solid Tumors
NCT00003709 ·Status: COMPLETED ·Phase: PHASE1
-
Open-Label Study to Assess the Safety/Tolerability in Patients With Solid Tumors
NCT00820560 ·Status: COMPLETED ·Phase: PHASE1
-
KRN5500 in Treating Patients With Solid Tumors
NCT00017238 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of Atezolizumab (Tecentriq®) in Ministry of Food and Drug Safety (MFDS)-Approved Indication(s)
NCT03232593 ·Status: COMPLETED
-
First-in-Human Trial of DS-2243a in Participants With Advanced Solid Tumors
NCT06644755 ·Status: RECRUITING ·Phase: PHASE1
-
Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery
NCT00608361 ·Status: COMPLETED ·Phase: PHASE1
-
MEN-10755 in Treating Patients With Solid Tumors
NCT00003982 ·Status: COMPLETED ·Phase: PHASE1
-
Chemotherapy in Treating Patients With Advanced or Metastatic Solid Tumors
NCT00003713 ·Status: COMPLETED ·Phase: PHASE1
-
5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors
NCT03366116 ·Status: RECRUITING ·Phase: PHASE1
-
Lenalidomide, Docetaxel, and Carboplatin in Treating Patients With Advanced Solid Tumors
NCT00415116 ·Status: COMPLETED ·Phase: PHASE1
-
CHS 828 in Treating Patients With Solid Tumors
NCT00003979 ·Status: WITHDRAWN ·Phase: PHASE1
-
Clinical Study to Evaluate Safety and Maximum Tolerated Dose of BAY1000394 Given in a 4 Week on / 2 Week Off Schedule in Subjects With Advanced Malignancies
NCT01335256 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of DCR-STAT3 in Adults With Solid Tumors
NCT06098651 ·Status: COMPLETED ·Phase: PHASE1
-
Tandem High Dose Chemotherapy With 131I-MIBG Treatment in High Risk Neuroblastoma
NCT03061656 ·Status: UNKNOWN ·Phase: PHASE2
-
CCI-779 in Treating Patients With Advanced Solid Tumors
NCT00003712 ·Status: COMPLETED ·Phase: PHASE1
-
AZD5438 in Patients With Advanced Solid Malignancies
NCT00088790 ·Status: COMPLETED ·Phase: PHASE1
-
Safety Assessment of One-hour Infusions of SNS-032 for the Treatment of Select Advanced Solid Tumors
NCT00292864 ·Status: COMPLETED ·Phase: PHASE1
-
Study of Dasatinib in Patients With Advanced Solid Tumors
NCT00162214 ·Status: TERMINATED ·Phase: PHASE1
-
SJG-136 in Treating Patients With Advanced Solid Tumors
NCT00103220 ·Status: COMPLETED ·Phase: PHASE1
-
SJG-136 in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery
NCT00121290 ·Status: COMPLETED ·Phase: PHASE1
-
Phase 1 Dose Escalation and Dose Expansion Trial of NP-101 in Patients With Solid Tumors
NCT06563375 ·Status: RECRUITING ·Phase: PHASE1
-
AZD1152 in Patients With Advanced Solid Malignancies
NCT00338182 ·Status: COMPLETED ·Phase: PHASE1
-
AZD6244 (ARRY-142886) Solid Oral Dosage Formulation in Participants With Advanced Solid Malignancies
NCT00463814 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Carbendazim in Treating Patients With Advanced Solid Tumors or Lymphoma
NCT00023816 ·Status: UNKNOWN ·Phase: PHASE1
-
Safety and Tolerability Study for T-1301 Capsules to Treat Advanced Solid Tumors
NCT05156203 ·Status: RECRUITING ·Phase: PHASE1